Clinical Trial Update: Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating safety, pharmacokinetics, and immunogenicity of BCD-256-1 and Divozilimab in adults with systemic lupus erythematosus; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• BCD-256-1 (BCD-256-1)
• Divozilimab (Divozilimab)

Snippet

Sponsor: Biocad | Conditions: Systemic Lupus Erthematosus | Phase 1 | Status: RECRUITING